A robust research and innovation ecosystem makes Italy an attractive life sciences hotspot, according to a post from an Italian trade delegation at Bio Digital 2021.
On April 12, 2021, Sequentia Biotech, a Spanish omics company, and NextBiomics, a biotech company involved in the research and development of Next Generation Probiotics and a spin-off of the Federico II University of Naples, announced the filing of a patent application for a bacterial vaccine against the COVID-19 syndrome.
By engineering the probiotic Escherichia Coli Nissle 1917 expressing the SARS-CoV-2 Spike protein, it was possible to obtain an innovative model of immunization against COVID-19 by stimulating the intestinal immune system”,
Giovanni Sarnelli
“The NEXBIOMICS vaccine is similar to others that have been already authorized (Pfizer, Moderna, AstraZeneca, Reithera, Johnson & Johnson) in that it stimulates the immune response against the Spike protein that the Coronavirus uses to infect cells, but it differs from them because it uses a probiotic bacterium as a vector, which is already on the market and being widely used for other purposes.
Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd
- Ian Nicholson stepping down to pursue non-executive roles
MANCHESTER, England and VIENNA, April 12, 2021 /PRNewswire/ F2G Limited ( F2G ), a clinical-stage biopharmaceutical company focused on life threatening fungal diseases, announces that Francesco Maria Lavino has been appointed Chief Executive Officer (CEO) and member of the Board of F2G. Mr. Lavino brings substantial specialty pharmaceutical leadership and expertise in the antifungal arena, including most notably, serving as AVP, Global Brand Leader, Anti-infectives portfolio at Merck & Co. and as Chief Commercial Officer of Nabriva Therapeutics, Inc. (NASDAQ: NBRV). Ian Nicholson is stepping down as CEO following eight years of dedicated service to F2G to pursue non-executive roles and will provide support to ensure an effective transition.